Bristol Myers Squibb (NYSE: BMY) has been sued by the former shareholders of Celgene, the company that it acquired in 2019.
The shareholders allege that BMS delayed the development of Breyanzi (lisocabtagene maraleucel) in order to avoid having to pay them $6.4 billion under a contingent value rights (CVRs) agreement which would have been due had the cancer drug won US approval by the end of 2020 —along with two other approvals relating to separate products and deadlines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze